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Abstract
MODY2 is the most prevalent monogenic form of diabetes in Italy with an estimated prevalence of about 0.5–1.5%. MODY2
is potentially indistinguishable from other forms of diabetes, however, its identification impacts on patients’ quality of life
and healthcare resources. Unfortunately, DNA direct sequencing as diagnostic test is not readily accessible and expensive. In
addition current guidelines, aiming to establish when the test should be performed, proved a poor detection rate. Aim of
this study is to propose a reliable and easy-to-use tool to identify candidate patients for MODY2 genetic testing. We
designed and validated a diagnostic flowchart in the attempt to improve the detection rate and to increase the number of
properly requested tests. The flowchart, called 7-iF, consists of 7 binary ‘‘yes or no’’ questions and its unequivocal output is
an indication for whether testing or not. We tested the 7-iF to estimate its clinical utility in comparison to the clinical
suspicion alone. The 7-iF, in a prospective 2-year study (921 diabetic children) showed a precision of about the 76%. Using
retrospective data, the 7-iF showed a precision in identifying MODY2 patients of about 80% compared to the 40% of the
clinical suspicion. On the other hand, despite a relatively high number of missing MODY2 patients, the 7-iF would not
suggest the test for 90% of the non-MODY2 patients, demonstrating that a wide application of this method might 1) help
less experienced clinicians in suspecting MODY2 patients and 2) reducing the number of unnecessary tests. With the 7-iF, a
clinician can feel confident of identifying a potential case of MODY2 and suggest the molecular test without fear of wasting
time and money. A Qaly-type analysis estimated an increase in the patients’ quality of life and savings for the health care
system of about 9 million euros per year.
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Introduction
Maturity-onset diabetes of the young type 2 (MODY2) is a
monogenic form of diabetes with autosomic dominant transmis-
sion caused by heterozygous, inactivating mutation in the
glucokinase gene (GCK). Loss-of-function GCK mutations impair
glucose-sensing of the pancreatic beta cells (and liver) that in turn
increase the threshold of pancreatic glucose-stimulated insulin
secretion [1–3]. As a result, MODY2 patients have a moderate,
not-progressive increase in fasting glucose and HbA1c levels and
impaired glucose tolerance at the oral glucose tolerance test. In
addition, carriers of GCK mutations are usually not prone to
micro- or macro-vascular complications and, with rare exceptions,
do not need pharmacological intervention [4].
It is now clearly established that MODY2 patients under
treatment with insulin or oral anti-diabetic drugs can discontinue
therapy without deterioration of their metabolic control. More-
over, inappropriate insulin treatment can induce iatrogenic weight
gain and onset of insulin resistance (D.I., personal observation, and
others [5,6]). In fact, the typical MODY2 patient requires less
frequent clinical surveillance than patients with other forms of
diabetes. As a consequence, to diagnose MODY 2, especially in
the pediatric age, is of paramount importance to ensure the
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appropriate clinical management and save healthcare resources
[7].
The exact prevalence of MODY of any type is unknown,
probably because their phenotypes overlap with the classical forms
of diabetes. Their overall prevalence is estimated at around 1% of
all diabetic cases, with MODY2 ranging from 30% to 60% of all
MODY sub-types depending on clinical setting and geographic
origin [8,9]. Various studies indicate that only a small proportion
of MODY are correctly identified. For instance, in the UK, only
5% to 20% of all patients theoretically affected by MODY are
predicted to be correctly diagnosed [9,10]. The number of patients
referred for MODY genetic testing differs widely among diabetic
clinics, and more experienced clinicians refer more patients for
testing while keeping a good detection rate [9].
Genetic testing is highly specific and sensitive and represents the
gold standard for diagnosing MODY2. However, this test has the
drawback of being still expensive and not easily accessible. In
2008, the European Molecular Genetics Quality Network
(EMGQN) published the guidelines for the selection of patients
for MODY molecular testing, thereby providing an important
common ground for European geneticists, pediatricians and
diabetologists [5]. The guidelines included most of the relevant
clinical parameters that define MODY, whereas others, such as
the assay of the autoantibodies responsible for classical type 1
diabetes, were not taken into account [11,12]. In this context, the
guidelines have a poor detection rate and diagnostic power that
can be improved, particularly in pediatrics, by adding other
clinical criteria [13,14].
Not all physicians treating diabetic patients have the expertise to
recognize the clinical features of genetic forms of diabetes.
Consequently, they hesitate to propose molecular testing, and it
is likely that many patients remain undiagnosed. In this scenario,
we designed and validated a 7-item flowchart (7-iF) to identify
patients that have a high probability of carrying GCK mutations,
thereby improving the detection rate and minimizing the number
of unnecessary tests. We chose to study this specific type of MODY
because is the commonest in Italy, at least in the pediatric
population [15,16], and because its diagnosis provides a percep-
tible impact on both patient’s quality of life (no need of treatment)
and health care costs (less frequent follow up visits, no stick for
glycemic controls or drugs to provide). The 7-iF consists of seven
questions with binary answers (yes/no) about data easily obtain-
able during a standard clinical examination, and therefore it can
be applied in all clinical settings. The 7-iF includes the most recent
criteria for the etiological diagnosis of diabetes (i.e. autoimmune
diabetes antibodies, HbA1c levels and familiarity) and is partic-
ularly addressed to general practitioners and physicians working
outside specialized centers, who are more prone to overlook this
diagnosis. Here we show that the 7-iF has high clinical utility in
comparison to the clinical suspicion alone and that a wide
application of this method might 1) help less experienced clinicians




The study was conducted according to the Helsinki II
declaration and it was approved by the Ethics Committee of the
School of Medicine Federico II, Naples, Italy. Written informed
consent to the study was obtained from each adult subject and
from both parents of children.
7-item flowchart
We defined the seven clinical, biochemical and anamnestic
criteria that best characterize a typical MODY2 patient: 1)
negative test for pancreatic autoimmune markers; 2) insulin
therapy naive; 3) HbA1c levels above or equal to 42 mmol/mol
(HbA1c= 6%) on at least one occasion; 4) diabetes/hyperglyce-
mia-onset ranging between 6 months and 25 years; 5) one parent
affected by diabetes of any type (type 1, type 2 or gestational) or
impaired fasting glucose (IFG) with or without impaired glucose
tolerance (IGT); 6) no signs or symptoms suggestive of different
types of diabetes (i.e., acanthosis nigricans, obesity, renal cysts,
deafness and retinopathy); and 7) without concurring severe
diseases, and not undergoing therapy that could impair glucose
homeostasis (Table S1).
Prospective evaluation of the 7-iF
We evaluated the clinical utility of the 7-iF in a ‘‘prospective
cohort’’ consisting of 921 patients followed-up at the diabetic
outpatient clinic of the Department of Pediatrics of the Second
University of Naples (S.U.N.). The 7-iF was validated in two
phases (Table 1).
Phase 1: database query
The electronic database containing the patients’ medical
records was queried to answer the first three items of the 7-iF
(autoimmunity, insulin therapy and HbA1c). All patients were
tested for at least two of the following autoantibodies islet cell
antibodies (ICA), glutamic acid decarboxylase (GAD), insulin
auto-antibodies (IAA), the islet beta-cell-specific zinc transporter 8
(ZnT8) and the IA-2 protein. The cohort was further filtered to
include only patients with no present or past insulin treatment and
with HbA1c levels . 42 mmol/mol (6%) at least in one
determination during their entire disease history. All patients
who passed these filters were invited to proceed to phase 2.
Phase 2: genetic and diabetologic counseling
We re-contacted selected patient and invited them to undergo
further investigations. We performed a clinical re-evaluation, and
genetic counseling of each compliant patient to obtain answers to
the remaining 7-iF items (items 4–7). Patients fulfilling all the
conditions were candidates for the genetic test. We prescribed the
genetic test for only one individual per family. In the prospective
cohort, we evaluated the precision of the 7-iF.
Molecular test
Genomic DNA from the selected patients was extracted from a
blood sample plus EDTA using the Nucleon BACC 2 kit
(Amersham Biosciences Europe, Milan, Italy). Exons and flanking
intron regions of GCK were amplified and sequenced as reported
elsewhere [16] with GenBank NM_000162 as reference sequence.
Variations were interpreted by comparison with those found in
100 non-diabetic Caucasian individuals of the same geographical
origin and with known pathological variations identified by
literature mining (www.hgmd.cf.ac.uk).
Retrospective validation
We validated the clinical utility of the 7-iF on 372 patients (‘‘first
retrospective cohort’’) addressed to the genetic test on the basis of
clinical suspicion and with a MODY2 diagnosis confirmed by
molecular test. This part of the study was conducted by physicians
of the Italian Study Group on Diabetes of the Italian Society of
Pediatric Endocrinology and Diabetology (ISPED) (Figure 1). The
‘‘first retrospective cohort’’ consisted of MODY2 patients from all
A Seven-Item Clinical Flowchart (7-iF) for MODY2
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over Italy to reduce population stratification and selection bias.
The cohort consisted of patients for whom complete medical
records were available; a single ‘‘unknown’’ to any of the 7-iF
questions was considered an exclusion criterion. The ‘‘second
retrospective cohort’’, including 210 patients, was composed by
the patients referred to (1) the Department of Molecular Medicine
and Medical Biotechnologies, University of Naples ‘‘Federico II’’-
CEINGE and (2) the Pediatrics Unit, IRCCS Casa Sollievo della
Sofferenza Hospital, S. Giovanni Rotondo (FG), with a clinical
suspicion of MODY2 and the indication to the genetic test. We
collected these latter data for patients referred in five years’ time,
before the beginning of the present study.
Results
Prospective evaluation of the 7-iF
To assess the clinical utility of the 7-iF, we evaluated clinical
records of the 921 patients followed in the Diabetic Outpatient
Clinic of the Department of Pediatrics of the Second University of
Naples with biochemical data of the autoimmune markers for type
1 diabetes (GAD, ICA, IAA, IA2 and the ZnT8). As described in
‘‘Materials and Methods’’, we applied a recursive filtering
approach to select patients (Table 1). Patients positive for an item
were queried about the next item. Among the 921 patients
enrolled in the study, 21 (2.3%) fulfilled the 7 items and 13 (1.4%)
had a positive genetic test. In detail, 310 (34%) patients were
negative for the autoimmune markers and, 256/310 (83%) had
not received insulin therapy. Of these 256 patients, 54 (21%) had
HbA1c levels higher than or equal to 42 mmol/mol (HbA1c$6%)
on at least one occasion. Among these 54 patients invited to
continue the study, 18 declined (unreachable or refused clinical re-
evaluation). During the clinical re-evaluation, we excluded a
further 15 patients: 4 because of a diabetes onset outside the age
range; 2 without an affected parent; 4 for signs of different types of
diabetes (1 with renal cysts, suspect MODY5; 3 with obesity and
acanthosis nigricans, suspect early onset type 2 diabetes), 4 for
concurrent severe diseases (2 with neurodevelopmental disorders
and dysmorphic features, 1 with congenital dyserythropoietic
anemia, 1 with acute lymphoblastic leukemia in remission) and 1
because a sibling in the study had already been identified as a
candidate for the genetic test. Consequently, 21/921 (2.3%)
patients were eligible for the test. Of these, 4 refused (unreachable
or refused genetic test) and 17 underwent the test. The diagnosis
was confirmed in 13/17 patients (Table 1), which corresponds to a
precision of our test of about the 76%.
Clinical features of the ‘‘prospective cohort’’
The principal clinical features of all ‘‘prospective cohort’’ cases,
both mutation negative and positive, are summarized in Tables S2
and S3. In a few cases, maximum HbA1c levels exceeded
53 mmol/mol (HbA1c= 7%); only in one case it exceeded
64 mmol/mol (HbA1c= 8%). Similarly, HbA1c level rarely fell
below 42 mmol/mol (HbA1c= 6%), which confirms the slightly
increased threshold of pancreatic glucose-stimulated insulin
secretion. As expected, compared with the initial sample, MODY2
patients were younger at diagnosis (p,0.001) and had significantly
lower values of maximum HbA1c (p= 0.019). MODY2 patients
were generally lean, with a BMI z-score close to zero and
maximum values usually below +1. On one occasion, a patient had
increased body weight, with a BMI z-score within the obesity
range (2.28), whereas his BMI z-score was usually around +1.
Retrospective validation of the 7-iF
We tested and validated the 7-iF on a large series of MODY2
cases, the ‘‘first retrospective cohort’’, recruited, merely on the
basis of the clinical suspicion, by the members of the Study Group
on Diabetes of the ISPED that is constituted by Italian hospital
and university clinics caring children with diabetes. All these
patients received a molecular diagnosis of MODY2 before the
beginning of the present study. Data from 19 Italian outpatients’
clinics and 5 medical genetics laboratories were pooled and
analyzed (Figure 1). Each patient was unequivocally identified by a
unique code to avoid overlapping. We received the records of 372
patients. Figure 2 summarizes the results of this retrospective
validation. The upper panel shows the percentage of patients
meeting each item. Most patients fulfilled each criterion. Although
satisfactory (around 80%), the single item with the lowest
prediction value was HbA1c. The lower panel shows the
Table 1. Validation of the 7-item flowchart.
Step N (%)
PHASE I (Database query) Initial cohort 921 (100%)
Item 1: Absence of autoimmune markers 310 (34%)
Item 2: Absence of current or past insulin therapy 256 (28%)
Item 3: HbA1c values $ 42 mmol/mol (6%) 54 (5.8%)
Clinical re-evaluation 36 (3.9%)a
PHASE II (Clinical
re-evaluation)
Item 4: Onset (diabetes or hyperglycemia) .6 m or ,25 y 32 (3.5%)
Item 5: Positive familiarity for either diabetes, IFG with or without IGT 30 (3.2%)
Item 6: Absence of signs of other types of diabetes (acanthosis nigricans, deafness, renal cystis) 26 (2.8%)
Item 7: Absence of other severe concurrent diseases 22 (2.4%)
No relatives enrolled in the study 21 (2.3%)
Molecular test 17 (1.8%)b
Results Positive for GCK mutation 13 (1.4%)
Phase I: The electronic records of the patients were queried (Items 1–3). Phase II, each selected patient was clinically re-evaluated (Items 4–7). IFG, impaired fasting
glucose; IGT, impaired glucose tolerance. aFirst drop out; 18 patients were unreachable or refused to undergo clinical re-evaluation. bSecond drop out; 4 patients
refused the genetic test.
doi:10.1371/journal.pone.0079933.t001
A Seven-Item Clinical Flowchart (7-iF) for MODY2
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percentage of MODY2 patients fulfilling the 7 items, 6 out of 7
items or less than 6 items. About 67% of the MODY2 patients
studied fulfilled 7 criteria out of 7, 25% of them proved positive to
6 out of 7 criteria and only 8% were positive just to 5 or 4 item of
the 7-iF. This result indicates that, if strictly applied on this cohort
of patients, the 7-iF would have correctly addressed to the genetic
test the 67% of these patients missing 33% of them.
In order to validate the precision of the 7-iF, we investigate a
‘‘second retrospective cohort’’ composed by 210 pediatric diabetic
patients referred, on the basis of the clinical suspicion, to two
genetic laboratories, the Department of Molecular Medicine and
Medical Biotechnologies, University of Naples ‘‘Federico II’’-
CEINGE and the Pediatrics Unit, IRCCS Casa Sollievo della
Sofferenza Hospital, S. Giovanni Rotondo (FG), to perform the
genetic test. All these patients were referred before the beginning
of this study. Among this 210 patients, 85 (40%) received a
confirmatory diagnosis of MODY2 whether 125 (60%) were
MODY2 negative proving a precision of the clinical suspicion of
40% (85/210) with 60% (125/210) of patients erroneously
addressed to the genetic test (false positive at the clinical suspicion).
To evaluate the clinical utility of the 7-iF in comparison to the
selection made upon the clinical suspicion, we calculated the 7-iF
score for all the patients of this ‘‘second retrospective cohort’’.
Sixty-four patients (64/210; 30%) were positive to the 7-iF (score:
7/7) and among them 52 were MODY2 proving a precision of the
7-iF in identifying MODY2 patients of about 81% (52/64) similar
to the 76% of the prospective evaluation. Among the 7-iF negative
patients, 77% (113/146) resulted non MODY2 and 22% (33/146)
MODY2. These 33 patients, corresponding to the about 39% of
all the MODY2 patients, would have been missed by the 7-iF. On
the other hand, 113 patients out of the 125 patients addressed to
the genetic test and resulted negative were correctly suspected by
the 7-iF as non-MODY2 (about 90% of true negative) further
Figure 1. P.I. and city of each participating ISPED centers. A. Fabrizio Barbetti (Roma), B. Corrado Mammı` (Reggio Calabria), C. Maurizio
Delvecchio (San Giovanni Rotondo), D1. Nadia Tinto (Napoli), D2. Enza Mozzillo (Napoli), E. Luigi Pianese (Ascoli Piceno), F. Sonia Toni (Firenze),
G. Bruno Pasquino (Bolzano), H. Valeria Calcaterra (Pavia), I. Ivana Rabbone (Torino), J. Barbara Felappi (Brescia), K. Francesca Cardella (Palermo),
L. Valentino Cherubini (Ancona), M. Franco Mammı` (Locri), N. Anna Paola Frongia (Cagliari), O. Francesco Gallo (Brindisi), P. Stefano Tumini (Chieti), Q.
Sonia Lucchesi (Livorno), R. Carla Maria Monciotti (Padova), S. Susanna Coccioli (Francavilla Fontana), T. Amedeo Vergerio ( deceased) (Feltre), U.
Stefano Zucchini (Bologna), V. Francesco Cadario (Novara), Riccardo Lera (Alessandria), X. Andrea Scaramuzza (Milano).
doi:10.1371/journal.pone.0079933.g001
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confirming the clinical utility of the 7-iF in helping less
experienced clinicians in suspecting MODY2 patients.
Discussion
The major issue with the MODY2 diagnosis is that, in general,
physicians rarely suspect MODY2 and, also whether happen,
many of them do not feel confident to ask for a molecular
diagnosis. Some of the reasons can be the lacking of clear
indications for the genetic test in the actual recommendations and
the little experience that many physician have with rare
monogenic disease. That might result in the estimated 80% of
MODY2 patients without a correct diagnosed [9].
Here we propose a simple flowchart, the 7-iF, to identify
candidates for the MODY2 genetic test. This flow-chart was
conceived to be used by all physicians dealing with diabetes: it does
not require specialized expertise in monogenic diabetes and is
designed to be easily implemented in daily clinical practice in an
outpatient setting. To explore its clinical utility, we evaluated its
precision in prospective cohort and validated the results in two
different retrospective cohorts. The 7-iF is broadly based on the
EMGQN guidelines [5] but, unlike the latter, it includes T1D
autoimmune markers and insulin treatment in the attempt to
exclude patients with type 1 diabetes, which is the most prevalent
form of diabetes (. 80%) in young individuals [11]. Consequently,
a rationale search for different forms of diabetes is justified only
when type 1 diabetes has been excluded. Although this strategy is
not included in the EMGQN guidelines [5], many researchers and
clinicians apply it [13,14,17,18]. Regarding insulin treatment,
most MODY2 patients have a modest impairment of glucose
metabolism and usually do not need pharmacological intervention
[17]. Therefore, patients with a positive history for insulin therapy
are less likely to carry a pathological GCK mutation; consequently,
only insulin-therapy naive patients are considered candidates for
the genetic test.
The other additional criteria of the 7-iF with respect to the
EMGQN guidelines are HbA1c levels, familiarity and age of
onset. We used HbA1c instead of fasting glucose or the oral
glucose tolerance test to select patients, because HbA1c reliably
distinguishes between episodic hyperglycemia and persistent
plasma glucose increase in the pathologic range. In fact, previous
data [17,19] and our clinical experience (Figure S1) indicate that a
considerable proportion of MODY2 patients show a normal 2-
hour glucose level at oral glucose tolerance tests. Indeed, recent
guidelines for diabetes diagnosis include HbA1c as diagnostic
marker [11,20], although a consensus on the threshold value has
yet to be reached. In the 7-iF, we use an HbA1c cut-off of
42 mmol/mol (HbA1c= 6%), which corresponds to a sub-diabetes
state [20]. Based on the 7-iF, only patients with at least one parent
affected by any alteration of glucose metabolism (type 1 or type 2
diabetes; gestational diabetes; IFG with or without IGT) are
considered candidates for genetic testing. This criterion was
included because MODY2 is an autosomal dominant inherited
disease, with rare de novo mutations described [17]. Familiarity is
not mandatory in the EMGQN guidelines [5], however recent
studies found that it is the most powerful factor in distinguishing
between MODY and sporadic forms of diabetes [10,13,14].
Furthermore, because MODY2 is usually discovered during
infancy or in early adulthood, a diagnosis before 25 years of age
is a criterion for the test in the 7-iF. Although a diagnosis of
diabetes before 6 months of life is highly suggestive of a genetic
cause, in such cases other types of monogenic diabetes (due to
mutations in KCNJ11, INS or ABCC8 genes) are more plausible
and should be evaluated before MODY2 [21]. Finally, the 7-iF
excludes from the genetic test, patients with complex, severe
clinical conditions, such as syndromic diseases, cancers, organ
failures. Although a GCKmutation can co-exist with other diseases,
patients with such features should be first evaluated by specialists
in genetic diabetes to determine whether their clinical conditions
cause the altered glucose metabolism or a pancreatic deficiency
really occurs.
In the present study, we showed that the precision of the 7-iF
was sufficiently high (76%) to make the tool appropriate for
routine application, especially if compared to precision of the
‘clinical suspect’ (40% estimated from the second retrospective
cohort). Furthermore, also considering the stringent 7-iF criteria
we diagnosed a number of patients not smaller than that expect in
a random diabetic population. In fact, we recommended the test to
17 patients of the prospective cohort and MODY2 was diagnosed
in 13 of them. This corresponds to a MODY2 frequency of 1.4%
(13/921), which is consistent with the expected frequency (0.56%–
1.56%) [9,15].
Despite the relatively high number of potentially missed cases
with the application of the 7-if in place of the clinical suspicion
(about 33% and 39% from the first and the second retrospective
cohort, respectively), considering the ability of the 7-iF in correctly
identify 76% of MODY2 patients in a general pediatric diabetic
population, together with the excellent ability in correctly identify
those patients with low chances of being MODY2 (about 90% of
true negative), we believe that a widely application of the 7-iF to all
the diabetic patients will result in an overall increase of the
MODY2 diagnosis. That because, the availability of clear
indications will increase the number of requested tests and will
result in a decrease of negative results (for the higher precision of
the 7-iF compared to the clinical suspicion). On the other hand,
lower score of positive items to the 7-iF (6/7) should not be
considered exclusion criteria. These latter patients would need
Figure 2. Validation on the ‘‘first retrospective cohort’’. (A)
Percentage of MODY2 patients positive to each item of the 7-iF. (B)
Percentage of MODY2 patients positive to 7, 6 or less than 6 items of
the 7-iF.
doi:10.1371/journal.pone.0079933.g002
A Seven-Item Clinical Flowchart (7-iF) for MODY2
PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e79933
further observation and eventually to be referred to center with
experience in monogenic diabetes, especially if they present
clinical features suggestive of genetic forms of diabetes, such as the
familiarity consistent with a dominant disease, similar clinical
features among familiars, and no necessity of insulin therapy in the
proband and other familiars even after many years of disease.
Recently, Shield et al. [10] proposed and validated a
mathematical model that estimates the probability that a diabetic
patient has of being affected by any of the three most common
forms of MODY, and reported the probability that each patient
had of being a carrier of a pathological mutation. At variance, the
7-iF serves to identify patients potentially affected specifically by
MODY2 (the most frequent MODY subtype reported in Italy
[15,16]) Interestingly, when we tested our retrospective cohorts for
the latter proposed model [10] we obtained less satisfactory
specificity (10%). This observation supports the use of the 7-iF as a
useful tool to improve the diagnosis of MODY2. Particularly,
providing as output a ‘‘yes or no’’ indication to the molecular test,
it is a very friendly to use during a standard clinical examination
by general practitioners.
During the prospective evaluation, several patients refused to
undergo further specialized diabetes and genetic investigations.
These patients, negative for autoimmunity markers, affected by
mild diabetes, without on-going therapy and with a good
glycaemia control, probably felt that further clinical evaluations
were not necessary. Considering the clinical characteristic of the
typical MODY2 patient, we believe this group to be enriched for
MODY2.
Detailed analysis of 7-iF output revealed that each item included
was frequent in MODY2 patients. In fact, almost all 7 items
elicited a ‘‘yes’’ answer in more than 90% of patients. Interestingly,
we found that most (. 90%) of the MODY2 patients met at least 6
of the 7-IF criteria and that the ‘‘missing’’ criterion was not always
the same (Figure 2A). This result suggests that a positive response
to any 6 of the 7 criteria of the 7-iF should be considered an
indication for the genetic test, irrespectively of which item is
missing. However, the precision of 6/7 items should be
prospectively evaluated before being implemented in clinical
practice.
The single item with the lowest prediction value was HbA1c
level with sensitivity around 80%; this is probably due to the high
threshold that we imposed. We selected a threshold that we
believed would balance two opposite goals: to test all patients with
a high suspicion of being MODY and to reduce the number of
tests to those with highest probability of being positive. This
threshold was chosen according to the International Expert
Committee’s definition of sub-diabetes status [20]. Of note, a
relevant number (15%) of GCK-mutation carriers evaluated in the
first retrospective cohort showed maximum HbA1c values slightly
below 42 mmol/mol (i.e.,6%). while less than 1% had HbA1c
levels above 64 mmol/mol (i.e. 8%) (Figure S2). Potentially,
lowering the HbA1c threshold to 38 mmol/mol (HbA1c= 5.6%),
or even using a range of HbA1c values from 38 mmol/mol to
64 mmol/mol (5.6%.HbA1c,8%), would improve the ability to
correctly identify potential MODY2 patients to address to the GCK
genetic test. However, these changes will need a prospective and
retrospective validation in different cohorts and we expect a
certain reduction of the specificity and of the positive prediction
value.
We believe that the 7-iF is a useful tool for all physicians dealing
with diabetic patients including those working outside the context
of a specialized center. Although the 7-iF ‘‘yes/no’’-approach
forces a continuous clinical spectrum into artificial stringent
threshold categories, it is probably the best way to make it
standardized and replicable. The power of this method is that it
does not require specific knowledge about this form of diabetes. In
fact, it could induce non-specialist clinicians, who are less prone to
consider MODY2 diabetes, to re-evaluate their strategy of
diagnosis. An implicit caveat is that more complex and uncertain
cases should be referred to specialized centers.
From a cost-effectiveness viewpoint, we believe that widespread
application of the 7-iF would result in optimization of healthcare
resources. By using QALY analysis (Material S1), we estimated
that the application of the 7-iF could provide an increase in the
quality of life and a saving for the health system of about 3000 in a
10 years period for every MODY2 diagnosed. Considering an
expected prevalence of at least 1% of MODY2 diabetic patients
among the Italian diabetic population [22] this would account for
a 9 million euro saving per year. Therefore, the initial cost of the
genetic test would be easily offset by the savings resulting from the
avoidance of life-long insulin therapy and three-month follow-ups.
The 7-iF criteria are highly specific for MODY2 and with no extra
costs except the autoantibody evaluations for each patient, which
are in any event recommended.
In conclusion, we provide the first simple set of binary items for
the identification of MODY2 patients that has been retrospectively
and prospectively validated. We demonstrate that the 7-iF is
reliable and with high precision in identifying MODY2 patients. It
can be easily implemented in all clinical settings to select patients
to undergo the MODY2 genetic test. This strategy will probably
increase the number of diagnoses of MODY2 with a consequent
considerable impact on the patient’s quality of life and on
healthcare resources.
Supporting Information
Figure S1 Oral Glucose Tolerance Test (OGTT) in
MODY2. Most GCK-MODY2 patients show basal level of
blood glucose above the normal range and high fasting glucose
levels (IFG) (basal glycaemia above 100 mg/dl). Nevertheless, a
considerable proportion of MODY2 patients show normal 2-hours
glucose level at oral glucose tolerance tests, with glycemic values
within the normal range or the impaired glucose tolerance (IGT).
(JPG)
Figure S2 Maximum HbA1c levels in MODY2 ascer-
tained patients. About the 80% of MODY2 patients investi-
gated in the retrospective cohort had, at least in one occasion,
HbA1c levels above or equal to 6% and, therefore, met the
flowchart’s criterion. Intriguingly a significant percentage of them
(15%) showed maximum HbA1c records between 5.6 and 6%.
(PDF)
Table S1 The 7-item flowchart.
(PDF)
Table S2 Clinical features of patients selected for the genetic test
in the prospective study.
(PDF)
Table S3 Clinical features of the patients in the prospective
study. Please note: Four patients are not included because positive
to the 7-iF but negative to the genetic test.
(PDF)
Material S1 The QALY analysis
(PDF)
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